A retrospective analysis showed that patients with epidermal growth factor receptor (EGFR) ‐mutant NSCLC were more likely to develop BMs than those with EGFR‐wild‐type NSCLC (31.4% vs. 19.7%, P < 0.001); moreover, BMs from EGFR‐mutant NSCLC often disseminate (30.8% vs. 12.7%).4 Ultimately, CNS metastases can become lethal in EGFR‐mutant NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.